(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33986023.
- Also identified by DOI 10.1158/1078-0432.CCR-21-1173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification.<i>See related article by Chen et al., p. 3990</i>.
Medical subject headings
- Immunotherapy
- Uterine Cervical Neoplasms